All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
APVO436 has been granted Orphan Drug Designation (ODD) for the treatment of patients with acute myeloid leukemia (AML) by the United States Food and Drug Administration (FDA).1 APVO436 is a bispecific antibody that is currently under investigation in patients with AML and myelodysplastic syndrome (MDS) in a phase I/Ib trial (NCT03647800).
APVO436 redirects T-cell cytotoxicity to tumor cells by targeting CD123 and CD3. APVO436 was developed using a proprietary platform, which can produce targeted bispecific antibodies with the ability to achieve potent biological activity and extended half-life. These antibodies can be used at lower concentrations than other bispecific antibody formats and can be built with a range of mechanisms of action.
ODD status means that a company is eligible to a seven-year exclusive marketing period and allows applications for funding for phase I and II clinical trials, with reduced market application filing fees and quicker regulatory processing.
Subscribe to get the best content related to AML delivered to your inbox